China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Financial Flexibility Index
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Financial Flexibility Index of 0.14x as of September 2025. Free cash flow of CN¥680.18 Million (operating CF CN¥487.90 Million minus capex CN¥192.28 Million) represents 0% of total liabilities (CN¥4.85 Billion). Check cash flow reinvestment rate of China Resources Double-Crane Pharmaceuti to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
China Resources Double-Crane Pharmaceutical Co Ltd Financial Flexibility Index (1998–2024)
Historical Financial Flexibility Index trend for China Resources Double-Crane Pharmaceutical Co Ltd across 27 annual periods. For the full cash flow conversion analysis, see how efficiently does China Resources Double-Crane Pharmaceuti generate cash.
Annual Financial Flexibility Index for China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)
Year-by-year free cash flow to debt coverage for China Resources Double-Crane Pharmaceutical Co Ltd. Explore 600062 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.44x | CN¥2.46 Billion | CN¥1.83 Billion | CN¥5.57 Billion | ▼ -29.0% |
| 2023 | 0.62x | CN¥2.27 Billion | CN¥1.65 Billion | CN¥3.64 Billion | ▲ +25.0% |
| 2022 | 0.50x | CN¥1.87 Billion | CN¥1.34 Billion | CN¥3.75 Billion | ▼ -13.1% |
| 2021 | 0.57x | CN¥1.83 Billion | CN¥1.34 Billion | CN¥3.20 Billion | ▲ +1.9% |
| 2020 | 0.56x | CN¥1.71 Billion | CN¥1.36 Billion | CN¥3.04 Billion | ▼ -13.1% |
| 2019 | 0.65x | CN¥1.68 Billion | CN¥1.44 Billion | CN¥2.60 Billion | ▼ -8.7% |
| 2018 | 0.71x | CN¥1.70 Billion | CN¥1.47 Billion | CN¥2.40 Billion | ▼ -16.1% |
| 2017 | 0.84x | CN¥1.34 Billion | CN¥1.19 Billion | CN¥1.59 Billion | ▲ +15.3% |
| 2016 | 0.73x | CN¥881.29 Million | CN¥771.25 Million | CN¥1.20 Billion | ▲ +11.9% |
| 2015 | 0.65x | CN¥869.83 Million | CN¥701.35 Million | CN¥1.33 Billion | ▼ -28.9% |
| 2014 | 0.92x | CN¥860.76 Million | CN¥718.38 Million | CN¥934.93 Million | ▲ +38.0% |
| 2013 | 0.67x | CN¥763.92 Million | CN¥546.24 Million | CN¥1.14 Billion | ▲ +94.5% |
| 2012 | 0.34x | CN¥617.94 Million | CN¥396.05 Million | CN¥1.80 Billion | ▼ -30.0% |
| 2011 | 0.49x | CN¥850.31 Million | CN¥511.53 Million | CN¥1.73 Billion | ▼ -28.7% |
| 2010 | 0.69x | CN¥879.85 Million | CN¥509.67 Million | CN¥1.28 Billion | ▲ +29.6% |
| 2009 | 0.53x | CN¥627.17 Million | CN¥342.01 Million | CN¥1.18 Billion | ▼ -7.4% |
| 2008 | 0.57x | CN¥640.91 Million | CN¥331.71 Million | CN¥1.12 Billion | ▲ +101.8% |
| 2007 | 0.28x | CN¥371.63 Million | CN¥235.46 Million | CN¥1.31 Billion | ▼ -24.5% |
| 2006 | 0.38x | CN¥475.37 Million | CN¥303.71 Million | CN¥1.26 Billion | ▲ +164.0% |
| 2005 | 0.14x | CN¥266.91 Million | CN¥139.78 Million | CN¥1.87 Billion | ▼ -49.7% |
| 2004 | 0.28x | CN¥650.55 Million | CN¥453.72 Million | CN¥2.30 Billion | ▲ +37.1% |
| 2003 | 0.21x | CN¥524.92 Million | CN¥148.94 Million | CN¥2.54 Billion | ▲ +5.8% |
| 2002 | 0.20x | CN¥392.62 Million | CN¥140.63 Million | CN¥2.01 Billion | ▼ -22.5% |
| 2001 | 0.25x | CN¥316.60 Million | CN¥141.01 Million | CN¥1.26 Billion | ▼ -39.0% |
| 2000 | 0.41x | CN¥259.63 Million | CN¥172.81 Million | CN¥628.89 Million | ▼ -2.9% |
| 1999 | 0.43x | CN¥201.40 Million | CN¥131.54 Million | CN¥473.60 Million | ▼ -27.2% |
| 1998 | 0.58x | CN¥116.51 Million | CN¥-13.78 Million | CN¥199.57 Million | — |